

Robert Knobler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5927479/publications.pdf>

Version: 2024-02-01

78
papers

11,220
citations

81839

39
h-index

69214

77
g-index

220
all docs

220
docs citations

220
times ranked

6229
citing authors

#	ARTICLE	IF	CITATIONS
1	WHO-EORTC classification for cutaneous lymphomas. <i>Blood</i> , 2005, 105, 3768-3785.	0.6	3,529
2	Revisions to the staging and classification of mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
3	Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy. <i>New England Journal of Medicine</i> , 1987, 316, 297-303.	13.9	1,192
4	Clinical End Points and Response Criteria in Mycosis Fungoides and SÅ©zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
5	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
6	EORTC consensus recommendations for the treatment of mycosis fungoides/SÅ©zary syndrome. <i>European Journal of Cancer</i> , 2006, 42, 1014-1030.	1.3	390
7	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/SÅ©zary syndrome â€” Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
8	A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. <i>Blood</i> , 2008, 112, 2667-2674.	0.6	320
9	Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 427-433.	0.6	238
10	Guidelines on the use of extracorporeal photopheresis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-37.	1.3	212
11	European Dermatology Forum S1â€”guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1401-1424.	1.3	148
12	Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresisâ€”Results of a Crossover Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1775-1782.	2.0	127
13	The PROCLIFI international registry of earlyâ€”stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
14	Extracorporeal photopheresis: Past, present, and future. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 652-665.	0.6	116
15	A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 950-957.	0.3	114
16	Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 33-50.	3.3	112
17	Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. <i>Blood</i> , 2014, 123, 290-299.	0.6	108
18	Blood classification and blood response criteria in mycosis fungoides and SÅ©zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56.	1.3	105

#	ARTICLE	IF	CITATIONS
19	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
20	Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. <i>Leukemia</i> , 2012, 26, 746-756.	3.3	97
21	Aggressive epidermotropic cutaneous CD8 ⁺ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. <i>Histopathology</i> , 2015, 67, 425-441.	1.6	86
22	Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1129-1133.	2.0	83
23	European dermatology forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1581-1594.	1.3	79
24	Extracorporeal Photopheresis—An Overview. <i>Frontiers in Medicine</i> , 2018, 5, 236.	1.2	72
25	Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ()	1.0	70
26	Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9. <i>British Journal of Dermatology</i> , 2015, 173, 93-105.	1.4	67
27	Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1313-1322.	1.9	61
28	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
29	Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. <i>Transfusion and Apheresis Science</i> , 2003, 28, 81-89.	0.5	57
30	Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?. <i>European Journal of Cancer</i> , 2007, 43, 2321-2329.	1.3	56
31	European dermatology forum " updated guidelines on the use of extracorporeal photopheresis 2020 " part 1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2693-2716.	1.3	49
32	CYTOKINE RELEASE BY PERIPHERAL BLOOD MONONUCLEAR CELLS IS AFFECTED BY 8-METHOXYPsorALEN PLUS UV-A. <i>Photochemistry and Photobiology</i> , 1994, 59, 182-188.	1.3	48
33	Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. <i>British Journal of Rheumatology</i> , 1997, 36, 1276-1282.	2.5	47
34	Extracorporeal photopheresis in acute and chronic graft-versus-host disease. <i>Transfusion and Apheresis Science</i> , 2014, 50, 349-357.	0.5	44
35	Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas. <i>Annals of the New York Academy of Sciences</i> , 2001, 941, 123-138.	1.8	42
36	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 250-257.	0.7	41

#	ARTICLE	IF	CITATIONS
37	Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 293-300.	0.9	41
38	Multiplex PCR for rapid detection of T-cell receptor gamma chain gene rearrangements in patients with lymphoproliferative diseases. <i>British Journal of Haematology</i> , 1996, 94, 136-139.	1.2	40
39	Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 829-836.	0.9	39
40	Role of Extracorporeal Photopheresis (ECP) in Treatment of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1747-1748.	2.0	39
41	Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIP) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.4	39
42	Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. <i>International Journal of Dermatology</i> , 2013, 52, 1308-1318.	0.5	35
43	Photopheresis (extracorporeal photochemotherapy). <i>Photochemical and Photobiological Sciences</i> , 2013, 12, 22-28.	1.6	31
44	Epidermal Elafin Expression Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2015, 135, 999-1006.	0.3	30
45	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 Part 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 27-49.	1.3	28
46	Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. <i>Haematologica</i> , 2014, 99, 1746-1752.	1.7	27
47	Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas. <i>Acta Dermato-Venereologica</i> , 2018, 98, 240-245.	0.6	20
48	Evaluation of safety and efficacy of variable pulsed light in the treatment of unwanted hair in 77 volunteers. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 311-315.	1.3	19
49	Sex steroid hormone receptor analysis in malignant melanoma. <i>British Journal of Dermatology</i> , 1982, 107, 54-59.	1.4	18
50	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIP) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.4	18
51	Recent advances in understanding and managing cutaneous T-cell lymphomas. <i>F1000Research</i> , 2020, 9, 331.	0.8	18
52	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.3	16
53	ECP and solid organ transplantation. <i>Transfusion and Apheresis Science</i> , 2014, 50, 358-362.	0.5	15
54	Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 215-221.	1.4	14

#	ARTICLE	IF	CITATIONS
55	Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1633-1636.	1.3	14
56	Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.. <i>Blood</i> , 2007, 110, 2561-2561.	0.6	12
57	Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 205-213.	0.7	11
58	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. <i>European Journal of Cancer</i> , 2018, 101, 278-280.	1.3	10
59	Photopheresis and the Red Man Syndrome. <i>Dermatology</i> , 1995, 190, 97-98.	0.9	9
60	Photoepilation with variable pulsed light in non-facial body areas: evaluation of efficacy and safety. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 518-523.	1.3	8
61	Extracorporeal photochemotherapy--present and future. <i>Vox Sanguinis</i> , 2000, 78 Suppl 2, 197-201.	0.7	8
62	Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015, 31, 175-183.	0.7	7
63	Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. <i>Journal of Dermatological Treatment</i> , 2020, 31, 91-98.	1.1	7
64	Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA. <i>Archives of Dermatological Research</i> , 1996, 288, 691-696.	1.1	6
65	Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients- A Pilot Study. <i>Transplant International</i> , 2022, 35, 10320.	0.8	6
66	Nitrogen mustard revisited. <i>British Journal of Dermatology</i> , 2014, 170, 495-495.	1.4	5
67	Cutaneous manifestations of acute and chronic graft-versus-host disease. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 76-87.	0.8	5
68	A potassium-titanyl-phosphate laser is an efficacious tool in the treatment of pyogenic granulomas. A retrospective study in 28 patients. <i>Photochemical and Photobiological Sciences</i> , 2019, 18, 343-348.	1.6	4
69	Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA. <i>Archives of Dermatological Research</i> , 1996, 288, 691-696.	1.1	3
70	Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). <i>European Journal of Cancer</i> , 2021, 156, S22-S23.	1.3	3
71	Effects of extracorporeal photopheresis on serum levels of vitamin D: Preliminary Data from a Pilot Study. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 51-53.	0.7	1
72	EORTC 21012: Phase II Multicentre Study of CaeLyx, C Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.. <i>Blood</i> , 2010, 116, 2823-2823.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Trafficking of 8-MOP Treated Leucocytes After Extracorporeal Photopheresis in Humans. Blood, 2011, 118, 1258-1258.	0.6	1
74	Tratamiento de linfomas cutáneos de células T con fotoinmunoterapia extracorpórea (Fotoféresis). Piel, 2011, 26, 523-531.	0.0	0
75	New developments in acute graft-versus-host disease. Memo - Magazine of European Medical Oncology, 2013, 6, 98-101.	0.3	0
76	Monitoring of B Cell Subpopulations in Patients with Chronic Graft-Versus-Host Disease May Predict Response to Extracorporeal Photopheresis. Blood, 2008, 112, 467-467.	0.6	0
77	Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease.. Blood, 2009, 114, 2226-2226.	0.6	0
78	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. Blood, 2010, 116, 4896-4896.	0.6	0